As Amarin approached their top-line data announcement at the end of September 2018, they had a few news releases related to the ESC and AHA conferences.

First, they issued back to back news releases on Aug 25 and Aug 26, 2018 to highlight their presentations at ESC 2018. These new releases summarized the data, announced a conference call to discuss the data, re-affirmed top-line expectations for REDUCE-IT by end of Sept 2018, and emphasized that REDUCE-IT is the next large CVOT set to report out results. With Resverlogix having two posters and a sponsored symposium at ESC 2019, as well as an imminent BETonMACE rationale, design and baseline data publication, we may see similar news release action from Resverlogix surrounding ESC 2019.

AMARIN’S REDUCE-IT™ CLINICAL STUDY NOW POSITIONED TO BE NEXT LARGE CARDIOVASCULAR OUTCOMES STUDY TO REPORT RESULTS

REAL-WORLD DATA SUPPORTS ASSOCIATION BETWEEN ELEVATED TRIGLYCERIDE LEVELS AND INCREASED PERIPHERAL ARTERIAL REVASCULARIZATION IN HIGH RISK STATIN-TREATED PATIENTS

Second, they issued a news release on Sept 12, 2018 (prior to REDUCE-IT top-line) announcing that the primary results for REDUCE-IT were accepted as a late breaking clinical trial presentation at the November 2018 AHA meeting. Again, they re-affirmed top-line expectations by end of Sept 2018. The deadline for late-breaking abstract submission for AHA 2019 is coming up next week. The AHA announces late breaking clinical trial schedule for AHA 2019 sometime mid- to late September.  However, the abstract authors are notified of acceptance prior to the AHA public announcement and I don't think there are any restrictions from the presenters acknowledging acceptance prior to the AHA public announcement. With Resverlogix currently expecting BETonMACE top-line data in September 2019, there could be announcement of BETonMACE late breaking abstract for AHA 2019. The latest Zacks SCR report mentioned the AHA 2019 conference as one of the planned venues for presenting BETonMACE results.

REDUCE-IT™ TRIAL PRIMARY RESULTS ACCEPTED FOR PRESENTATION AT 2018 SCIENTIFIC SESSIONS OF AMERICAN HEART ASSOCIATION